Appendix Table 4.

Outcomes with FIT screening strategies that vary by the ages to begin and end screening among non-transplant Cystic Fibrosis patients.

	Outcomes per 1,000 non-transplant cystic fibrosis individuals free of diagnosed cancer at age 30 years in 2017 (3% discounted)
	Screening tests		Surveillance COLs	Total COLs	Compli -cations	CRC Casesc	CRC deatha,c	LY with CRC	LYGb	Total costs (*$1,000)	Net costs (*$1,000)	Reductionsb CRC incidencec	(%) CRC mortalityc	Efficient strategy
	FIT	COLs
No screening	0	23	0	23	0	52	19	134	0	1918503	0	0	0	Dominated
FIT 50–55 y	864	0	120	210	1	45	12	153	19	2038443	119940	13	37	Dominated
FIT 50–60 y	1164	0	148	255	1	43	9	158	25	2052169	133666	18	50	Dominated
FIT 50–65 y	1300	0	158	273	2	42	8	161	27	2063754	145251	20	58	Dominated
FIT 50–70 y	1353	0	161	279	2	42	7	163	28	2072133	153630	20	61	Dominated
FIT 50–75 y	1369	0	162	281	2	42	7	163	28	2074725	156222	20	62	Dominated
FIT 45–55 y	1959	0	194	329	2	42	10	155	28	2115102	196599	19	48	Dominated
FIT 45–60 y	2228	0	216	366	2	40	8	159	32	2126869	208366	23	59	Dominated
FIT 45–65 y	2352	0	226	382	2	40	7	162	34	2137804	219302	25	65	Dominated
FIT 45–70 y	2400	0	228	388	2	39	6	163	35	2145442	226939	25	69	Dominated
FIT 45–75 y	2416	0	229	389	2	39	6	164	35	2148080	229577	25	70	Dominated
FIT 40–55 y	3696	0	268	463	2	40	9	155	34	2252661	334158	23	54	Dominated
FIT 40–60 y	3948	0	288	497	2	39	7	159	38	2266287	347784	27	64	Dominated
FIT 40–65 y	4064	0	296	512	2	38	6	162	40	2276322	357819	28	70	Dominated
FIT 40–70 y	4110	0	299	517	2	38	5	163	41	2283302	364799	28	73	Dominated
FIT 40–75 y	4125	0	300	519	2	38	5	164	41	2286016	367513	28	75	Efficient
FIT 35–55 y	6360	0	336	622	2	39	8	155	39	2469942	551440	26	58	Dominated
FIT 35–60 y	6602	0	356	654	2	37	6	159	43	2482622	564119	29	68	Dominated
FIT 35–65 y	6714	0	364	668	2	36	5	162	45	2492455	573952	30	74	Dominated
FIT 35–70 y	6758	0	366	674	2	36	4	163	45	2498628	580125	31	77	Dominated
FIT 35-75 y	6772	0	367	675	2	36	4	163	46	2501004	582501	31	78	Optimal
FIT 30–55 y	10379	0	397	821	2	38	8	155	42	2800037	881534	27	61	Dominated
FIT 30–60 y	10616	0	416	852	2	36	6	159	46	2812063	893560	30	70	Dominated
FIT 30–65 y	10726	0	424	866	2	36	5	161	48	2821545	903042	32	76	Dominated
FIT 30–70 y	10769	0	427	871	2	36	4	162	49	2828060	909557	32	78	Dominated
FIT 30–75 y	10783	0	427	872	2	36	4	163	49	2830319	911816	32	80	Efficient

COL indicates colonoscopy; CRC, colorectal cancer; LY, Life-years; LYG, LY gained compared with no screening; FIT , Fecal immunochemical test; Grey row indicates optimal screening strategy.

^aIncluding deaths from complications of screening;

^bcompared with no screening;

^cCRC cases and CRC death were not discounted.